Repurposing Thymoquinone as Therapy for Metastatic Castration-Resistant Prostate Cancer

Abstract

The primary goal of this project is to elucidate the mechanism of action of thymoquinone (TQ) against docetaxel (DTX)-resistant, metastatic castration-resistant prostate cancer (mCRPC). We formulated a novel TQ nanoparticles (NPs) capable of rapid clinical translation; we utilized a highly innovative-patented NP platform, the planetary ball-milling (PBM) platform. In this study, we investigate whether thymoquinone directly inhibits ABCB1 transporter activity in mCRPC cells. We found that TQ can now bind and inhibit the transporter activity of ABCB1, thereby enhancing the cytotoxicity of DTX in mCRPC cells. We have also identified thymoquinone inhibits the transcription of ABCB1 through a ZEB1-dependent mechanism.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2020
Accession Number
AD1112435

Entities

People

  • Rajesh Singh

Organizations

  • Morehouse School of Medicine

Tags

DTIC Thesaurus Topics

  • Cell Physiological Processes
  • Cells
  • Chemical Synthesis
  • Chemistry
  • Chemotherapy
  • Gene Expression
  • Medical Personnel
  • Microscopes
  • Nanoparticles
  • Neoplasms
  • Oncology
  • Peptide Growth Factors
  • Prostate Cancer
  • Surface Plasmon Resonance

Fields of Study

  • Biology

Readers

  • Oncology (Cancer Research).
  • Prostate Cancer Biology.

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech